Nicotinic Ach Receptors

Total Page:16

File Type:pdf, Size:1020Kb

Nicotinic Ach Receptors Nicotinic ACh Receptors Susan Wonnacott and Jacques Barik Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK Susan Wonnacott is Professor of Neuroscience in the Department of Biology and Biochemistry at the University of Bath. Her research focuses on understanding the roles of nicotinic acetylcholine receptors in the mammalian brain and the molecular and cellular events initiated by acute and chronic nicotinic receptor stimulation. Jacques Barik was a PhD student in the Bath group and is continuing in addiction research at the Collège de France in Paris. Introduction and there followed detailed studies of the properties The nicotinic acetylcholine receptor (nAChR) is the of nAChRs mediating synaptic transmission at prototype of the cys-loop family of ligand-gated ion these sites. nAChRs at the muscle endplate and in sympathetic ganglia could be distinguished channels (LGIC) that also includes GABAA, GABAC, by their respective preferences for C10 and C6 glycine, 5-HT3 receptors, and invertebrate glutamate-, histamine-, and 5-HT-gated chloride channels.1,2 polymethylene bistrimethylammonium compounds, 7 nAChRs in skeletal muscle have been characterised notably decamethonium and hexamethonium. This DRIVING RESEARCH FURTHER in detail whereas mammalian neuronal nAChRs provided the first evidence that muscle and neuronal DRIVING RESEARCH FURTHER in the central nervous system have more recently nAChRs are structurally different. become the focus of intense research efforts. This In the 1970s, elucidation of the structure and function was fuelled by the realisation that nAChRs in the brain of the muscle nAChR, using biochemical approaches, and spinal cord are potential therapeutic targets for was facilitated by the abundance of nicotinic synapses a range of neurological and psychiatric conditions. akin to the muscle endplate in electric organs of the The generation of transgenic mice with deleted or electric ray, Torpedo, and eel, Electrophorus. High mutated nAChR subunits3 and the development affinity snake α-toxins, including α-bungarotoxin of subtype-selective ligands to complement the (α-Bgt), enabled the nAChR protein to be purified generous armamentarium of natural products that and subsequently resolved into 4 different subunits, target nAChRs,4 support this research. Progress is designated α,β,γ and δ.8 An additional subunit, ε, was being made in understanding the physiological roles subsequently identified in adult skeletal muscle. In of nAChRs in the brain and the underlying molecular the early 1980s, these subunits were cloned and the and cellular mechanisms, and the contribution of era of the molecular analysis of nAChRs commenced. nAChRs to pathological conditions. The muscle endplate nAChR has the subunit combination and stoichiometry (α1) β1εδ, whereas Muscle nAChR 2 the extrajunctional nAChR (α1)2β1γδ predominates nAChRs in vertebrate skeletal muscle have been in foetal or denervated muscle, and (muscle-derived) studied for over a century; this preparation was electric organs. The high density of nAChRs in Torpedo pivotal in Langley’s formulation of the concept electric organ has facilitated high resolution structural 5 of a ‘receptive substance’. In these studies he studies using electron microscopy.9 Together with showed that ‘nicotine causes tonic contraction of biochemical and biophysical approaches to studying certain muscles of fowl, frog and toad, and that this structure-function relationships, this has resulted in a contraction is prevented .... by curare’. This was detailed molecular description of the nAChR.1 the first notion that the action of a neurotransmitter or pharmacological agonist is transduced into an Molecular Architecture of the nAChR intracellular response by interaction with a molecular (Figure 1) entity (‘receptor’) in the membrane of the responsive Each of the five subunits comprising the nAChR span cell. Dale distinguished the actions of muscarine the lipid bilayer to create a water-filled pore. Each and nicotine, leading to the recognition of two subunit consists of 4 transmembrane segments, pharmacologically distinct (and structurally and the second transmembrane segment (M2) lines the functionally unrelated) families of receptors for the ion channel. The extracellular N-terminal domain neurotransmitter acetylcholine (ACh), that take their of every subunit contains a ‘cys-loop’ that is the names from these natural products.6 Neuromuscular signature sequence of this LGIC family: two cysteine and ganglionic preparations lend themselves to residues, separated by 13 amino acids (Cys 128, physiological and pharmacological investigations, 142, Torpedo α subunit numbering), form a disulphide Tocris Bioscience Scientific Review Series Tocris Bioscience Scientific Review Series Figure 1 | General structure of nAChRs1 Non-competitive Antagonist K+ Positive Allosteric Agonist / Competitive Complementary Modulator Antagonist binding site: γ/(δ) Channel Blocker Primary E D binding site: α Y B Y111 117 W149 W55/(57) Y151 F Nic D180/(182) Y190 C C192 C193Y198 Y W86 a) N b) 93 A ACh binding protein Cys-loop C C 2+ + Ca , Na C M1 M2 M3 M4 M2 lines c) the channel a) Schematic of a nAChR with one subunit removed to reveal the ion channel lumen. Notional sites of action of interacting drugs in the extracellular domain or within the channel lumen are indicated. b) Agonist binding site loop model. The agonist binding site is enlarged to show the contributing polypeptide loops forming the primary and complementary components, with key amino acids indicated on the loops. c) The topography of a single subunit. bond to create a loop that has been implicated in californica and Bulinus truncatus.12,13 Each subunit the transduction of agonist binding into channel of this pentameric secreted protein is homologous opening.10 The principal agonist binding site resides to the N-terminal domain of a nAChR subunit, with in the N-terminal domain of α subunits, close to a pair conservation of all the residues implicated in ACh of adjacent (‘vicinal’) cysteine residues (Cys 192, binding to muscle nAChRs. These proteins provide a 193, Torpedo numbering) that define an α subunit. high resolution view of the extracellular portion of the Mutagenesis and photoaffinity labelling experiments receptor, notably of the binding sites at the interface have highlighted the importance of 4 aromatic between adjacent subunits, and the interaction of residues (Tyr 93, Trp 149, Tyr 190, Tyr 198, Torpedo agonists with these sites.10 numbering), consistent with 3 polypeptide loops of Upon agonist binding, nAChRs undergo an allosteric the α subunit (loops A-C) contributing to the primary 11 transition from the closed, resting conformation to agonist binding site (see Figure 1). The adjacent an open state that allows an influx of Na+, and to a subunit (γ/ε or δ) also contributes to the binding site lesser extent Ca2+, and an efflux of K+ under normal (complementary site: ‘loops’ D-F, now recognised to physiological conditions. In the closed state the ion be mostly β strands). One consequence of this is that channel is occluded by a ‘hydrophobic girdle’ that the αγ/ε and αδ binding sites are not identical with 1 constitutes a barrier to ion permeation. Agonist respect to ligand affinity. However, occupancy of binding in the extracellular domain promotes a both binding sites is required to open the channel. conformational change that results in a rotational Knowledge of ligand binding to nAChRs has been movement of the M2 helices lining the pore. Twisting greatly augmented by the crystal structure of an ACh of the girdle widens the pore by ~3 Å, sufficient for binding protein first identified in the snail Lymaea ion permeation.9 At the muscle endplate, the ensuing stagnalis and subsequently also cloned from Aplysia depolarisation elicits muscle contraction. Despite the | Nicotinic Receptors presence of agonist, the nAChR channel closes within seconds to minutes, to enter a desensitised state. In Figure 2 | Relationship between the major this condition, the nAChR is refractory to activation. conformational states of a nAChR Multiple desensitised states have been proposed to agonist exist.14 In the active (open) conformation, the nAChR RESTING ACTIVE Channel closed Channel open Agonist binds binds agonists with low affinity (Figure 2; e.g. Kd for with low affinity ACh ~50 μM). The desensitised states display higher affinity for agonist binding (Kd for ACh ~1-5 μM), thus the desensitised nAChRs can retain bound agonist despite its non-conducting state. DESENSITISED Fast onset Sites on the Muscle nAChR for Ligand Agonist binds Interactions (Figure 1) with high affinity In addition to agonists binding to the agonist binding sites in the extracellular domain, competitive DESENSITISED antagonists also bind at or close to these sites, Slow onset preventing access to agonists. Their antagonism can be overcome by increasing the agonist concentration (unless the antagonist binds irreversibly, as is the agonist binding sites, and include channel blocking case for α-Bgt), hence competitive antagonism is drugs that occlude the channel. Their inhibition is not referred to as ‘surmountable’. The concentration surmountable with increasing agonist concentration. of competitive antagonist necessary for nAChR In addition to compounds that interact specifically blockade will depend on the experimental conditions. with residues in the mouth or lumen of the pore, any Non-competitive antagonists bind to sites distinct from small positively
Recommended publications
  • The Pharmacology of Autonomic Failure: from Hypotension to Hypertension
    1521-0081/69/1/53–62$25.00 http://dx.doi.org/10.1124/pr.115.012161 PHARMACOLOGICAL REVIEWS Pharmacol Rev 69:53–62, January 2017 Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: STEPHANIE W. WATTS The Pharmacology of Autonomic Failure: From Hypotension to Hypertension Italo Biaggioni Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee Abstract .....................................................................................53 I. Introduction . ...............................................................................54 A. Overview of Normal Cardiovascular Autonomic Regulation ...............................54 B. The Baroreflex . .........................................................................54 C. Pathophysiology of Orthostatic Hypotension and Autonomic Failure. ....................54 D. Ganglionic Blockade as a Pharmacological Probe To Understand Autonomic Failure.......55 E. Autonomic Failure as a Model To Understand Pathophysiology . ..........................55 II. Targeting Venous Compliance in the Treatment of Orthostatic Hypotension...................55 III. Pharmacology of Volume Expansion. .......................................................56 Downloaded from A. Fludrocortisone . .........................................................................56 B. Erythropoietin . .........................................................................56 IV. Replacing Noradrenergic Stimulation
    [Show full text]
  • Chemicals in the Fourth Report and Updated Tables Pdf Icon[PDF
    Chemicals in the Fourth National Report on Human Exposure to Environmental Chemicals: Updated Tables, March 2021 CDC’s Fourth National Report on Human Exposure to Environmental Chemicals: Updated Tables, March 2021 provides exposure data on the following chemicals or classes of chemicals. The Updated Tables contain cumulative data from national samples collected beginning in 1999–2000 and as recently as 2015-2016. Not all chemicals were measured in each national sample. The data tables are available at https://www.cdc.gov/exposurereport. An asterisk (*) indicates the chemical has been added since publication of the Fourth National Report on Human Exposure to Environmental Chemicals in 2009. Adducts of Hemoglobin Acrylamide Formaldehyde* Glycidamide Tobacco Alkaloids and Metabolites Anabasine* Anatabine* Cotinine Cotinine-n-oxide* Hydroxycotinine* Trans-3’-hydroxycotinine* 1-(3-Pyridyl)-1-butanol-4-carboxylic acid* Nicotine* Nicotine-N’-oxide* Nornicotine* Tobacco-Specific Nitrosamines (TSNAs) N’-Nitrosoanabasine (NAB)* N’-Nitrosoanatabine (NAT)* N’-Nitrosonornicotine (NNN)* Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) (NNAL)* Volatile N-nitrosamines (VNAs) N-Nitrosodiethylamine (NDEA)* N-Nitrosoethylmethylamine (NMEA)* N-Nitrosomorpholine (NMOR)* N-Nitrosopiperidine (NPIP)* N-Nitrosopyrrolidine (NPYR)* Disinfection By-Products Bromodichloromethane Dibromochloromethane Tribromomethane (Bromoform) Trichloromethane (Chloroform) Personal Care and Consumer Product Chemicals and Metabolites Benzophenone-3 Bisphenol A Bisphenol F* Bisphenol
    [Show full text]
  • Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence
    Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence Christie D. Fowler, Jill R. Turner, and M. Imad Damaj Contents 1 Introduction 2 Basic Neurocircuitry of Nicotine Addiction 3 Role of Nicotinic Receptors in Nicotine Dependence and Brain Function 4 Modulatory Factors That Influence nAChR Expression and Signaling 5 Genomics and Genetics of Nicotine Dependence 5.1 Overview 5.2 Human and Animal Genetic Studies 5.3 Transcriptionally Adaptive Changes 6 Other Constituents in Nicotine and Tobacco Products Mediating Dependence 7 Therapeutic Approaches for Tobacco and Nicotine Dependence 7.1 Nicotine Replacement Therapies 7.2 Varenicline and Bupropion 7.3 Novel Approaches 8 Conclusion References Abstract Tobacco dependence is a leading cause of preventable disease and death world- wide. Nicotine, the main psychoactive component in tobacco cigarettes, has also C. D. Fowler Department of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA J. R. Turner Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA M. Imad Damaj (*) Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Translational Research Initiative for Pain and Neuropathy at VCU, Richmond, VA, USA e-mail: [email protected] # Springer Nature Switzerland AG 2019 Handbook of Experimental Pharmacology, https://doi.org/10.1007/164_2019_252 C. D. Fowler et al. been garnering increased popularity in its vaporized form, as derived from e-cigarette devices. Thus, an understanding of the molecular mechanisms under- lying nicotine pharmacology and dependence is required to ascertain novel approaches to treat drug dependence. In this chapter, we review the field’s current understanding of nicotine’s actions in the brain, the neurocircuitry underlying drug dependence, factors that modulate the function of nicotinic acetylcholine receptors, and the role of specific genes in mitigating the vulnerability to develop nicotine dependence.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • 111 Physiology, Biochemistry and Pharmacology
    Reviews of 111 Physiology, Biochemistry and Pharmacology Editors M. P. Blaustein, Baltimore • H. Grunicke, Innsbruck E. Habermann, Giel3en • H. Neurath, Seattle S. Numa, Kyoto • D. Pette, Konstanz B. Sakmann, G6ttingen • U. Trendelenburg, Wiirzburg K.J. Ullrich, Frankfurt/M With 32 Figures and 10 Tables Springer-Verlag Berlin Heidelberg New York London Paris Tokyo ISBN 3-540-19156-9 Springer-Verlag Berlin Heidelberg NewYork 1SBN 0-387-19156-9 Springer-Verlag NewYork Berlin Heidelberg Library of Congress-Catalog-Card Number 74-3674 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its version of June 24, 1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1988 Printed in Germany The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant pro- tective laws and regulations and therefore free for general use. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Typesetting:K+ V Fotosatz, Beerfelden Offsetprinting and Binding: Konrad Triltsch, D-8700 W~rzburg 2127/3130-543210- Printed on acid-free paper Contents Regulation of Blood Pressure by Central Neuro- transmitters and Neuropeptides By A.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Effects of the Nicotinic Agonist Varenicline, Nicotinic Antagonist R-Bpidi, and DAT Inhibitor R-Modafinil on Co-Use of Ethanol and Nicotine in Female P Rats
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Psychopharmacology Manuscript Author (Berl) Manuscript Author . Author manuscript; available in PMC 2019 May 01. Published in final edited form as: Psychopharmacology (Berl). 2018 May ; 235(5): 1439–1453. doi:10.1007/s00213-018-4853-4. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor R-modafinil on co-use of ethanol and nicotine in female P rats. Sarah E. Maggio1, Meredith A. Saunders1, Thomas A. Baxter1, Kimberly Nixon2, Mark A. Prendergast1, Guangrong Zheng3, Peter Crooks3, Linda P. Dwoskin2, Rachel D. Slack4, Amy H. Newman4, Richard L. Bell5, and Michael T. Bardo1 1Department of Psychology, University of Kentucky, Lexington, KY 40536, USA. 2Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. 3Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas, Little Rock, AR 72205, USA. 4Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse- Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, USA. 5Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Abstract Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, 2-bottle choice); (2) nicotine alone (0.03 mg/kg/infusion, active vs.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels
    Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels by Shababa Tanzeel Masoud A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Pharmacology and Toxicology University of Toronto © Copyright by Shababa Tanzeel Masoud 2017 Characterization of Mice with Altered Dopamine Transporter and Vesicular Monoamine Transporter 2 Levels Shababa Tanzeel Masoud Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto 2017 Abstract Dopamine is a key neurotransmitter that regulates motor coordination and dysfunction of the dopamine system gives rise to Parkinson’s disease. Nigrostriatal dopamine neurons are vulnerable to various genetic and environmental insults, suggesting that these cells are inherently at-risk. A cell-specific risk factor for these neurons is the neurotransmitter, dopamine itself. If intracellular dopamine is not appropriately sequestered into vesicles, it can accumulate in the cytosol. Cytosolic dopamine is highly reactive and can trigger oxidative stress, leading to cellular toxicity. Cytosolic dopamine levels are modulated by the plasma membrane dopamine transporter (DAT) that takes up dopamine from the extracellular space, and the vesicular monoamine transporter 2 (VMAT2) that stores dopamine into vesicles. In this thesis, we altered DAT and VMAT2 levels to investigate the detrimental consequences of potentially amplifying cytosolic dopamine in transgenic mice. Project 1 focused on selective over-expression of DAT in dopaminergic cells of transgenic mice (DAT-tg). DAT-tg mice displayed phenotypes of dopaminergic damage: increased dopamine-specific oxidative stress, L-DOPA-reversible fine motor deficits and enhanced sensitivity to toxicant insult, suggesting that increasing DAT- mediated dopamine uptake is detrimental for dopamine cells.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Biomarkers of Exposure Among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013-14)
    Author Manuscript Published OnlineFirst on January 27, 2020; DOI: 10.1158/1055-9965.EPI-19-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013-14) Running Title: Biomarkers of Exposure in PATH Study Smokeless Tobacco Users Yu-Ching Cheng1, Carolyn M. Reyes-Guzman1,2, Carol H. Christensen1, Brian L. Rostron1, Kathryn C. Edwards3, Lanqing Wang4, Jun Feng4, Jeffery M. Jarrett4, Cynthia D. Ward 4, Baoyun Xia4, Heather L. Kimmel5, Kevin Conway5, Carmine Leggett1, Kristie Taylor3, Charlie Lawrence3, Ray Niaura6, Mark J. Travers7, Andrew Hyland7, Stephen S. Hecht8, Dorothy K. Hatsukami8, Maciej L. Goniewicz7, Nicolette Borek1, Benjamin C. Blount4, Dana M. van Bemmel1 1Center for Tobacco Products, Food and Drug Administration, MD, USA, 2National Cancer Institute, National Institutes of Health, MD, USA, 3Westat, MD, USA, 4US Centers for Disease Control and Prevention, USA, 5National Institute on Drug Abuse, National Institutes of Health, MD, USA, 6New York University College of Global Public Health, NY, USA, 7Roswell Park Cancer Institute, NY, USA, 8University of Minnesota, Masonic Cancer Center, USA. Key Words: biomarkers of exposure, smokeless tobacco Corresponding author: Yu-Ching Cheng, PhD 11785 Beltsville Drive, RM 8321 Beltsville, MD 20705 [email protected] 240-402-5957 1 Downloaded from cebp.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 27, 2020; DOI: 10.1158/1055-9965.EPI-19-0766 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]